PDCD1 and cancer: Immune checkpoint inhibition (ICI) has become a standard treatment to re-invigorate tumor-attacking T cell responses in multiple cancer indications, yet a patient’s response is unpredictable even with a confirmed expression of the relevant targets such as PD-1 or PD-L1.